Article | October 31, 2018

5 Reasons To Integrate Model-Based Meta-Analyses (MBMA) Into Your Clinical Development Strategy

Source: Cytel

By Esha Senchaudhuri

Clinical Trial Protocol

An important trend in clinical development involves integrating strategic pharmacometric analysis with program level decision-making, to make the most use of available data. This can occur in various forms, from leveraging preclinical data for go-no-go decision making, to the need for improved comparative effectiveness frameworks.

Here we have five reasons why you should consider utilizing model-based meta-analyses ( MBMAs)  for your program or portfolio development.